世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

乳児けいれん治療薬の世界市場 2024-2028


Global Infantile Spasms Therapeutics Market 2024-2028

乳児けいれん治療薬の世界市場 2024-2028 小児けいれん治療薬市場は2023年から2028年にかけて8961万米ドル成長し、予測期間中のCAGRは5.41%で加速すると予測されます。この調査レポートは、乳児けいれん治療薬市... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechNavio
テクナビオ
2023年12月13日 US$2,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
154 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

乳児けいれん治療薬の世界市場 2024-2028
小児けいれん治療薬市場は2023年から2028年にかけて8961万米ドル成長し、予測期間中のCAGRは5.41%で加速すると予測されます。この調査レポートは、乳児けいれん治療薬市場の全体的な分析、市場規模や予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。同市場は、神経学およびてんかんの研究の進歩、小児けいれんおよび関連神経疾患の有病率の上昇による小児けいれん治療薬に対する需要の増加、小児けいれんの早期診断に対する意識の高まりと重視によって牽引されています。
Technavioの小児けいれん治療薬市場は以下のように区分されています:
投与経路別
- 非経口剤
- 経口
薬物クラス別
- 抗けいれん薬
- 副腎皮質ステロイド
- その他
地域別
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)
本調査では、遺伝子治療への関心の高まりが、今後数年間の小児けいれん治療薬市場の成長を促進する主要な理由の1つであると特定しています。また、製薬会社、研究機関、支援団体間の協力による、デジタルヘルスソリューションの統合や小児けいれん治療薬の進歩の増加は、市場の大きな需要につながるでしょう。
この調査レポートは、小児けいれん治療薬市場を調査・分析し、以下の刊行物を刊行しました:
- 小児けいれん治療薬市場のサイジング
- 小児痙攣治療薬市場予測
- 乳児けいれん治療薬市場の産業分析
本レポートでは、クライアントが市場での地位を向上できるよう、しっかりとしたベンダー分析を行い、それに沿って、Amneal Pharmaceuticals Inc、Intas Pharmaceuticals Ltd.、Jazz Pharmaceuticals Plc、Mallinckrodt Plc、Marinus Pharmaceuticals Inc.、MSN Laboratories、Ovid Therapeutics Inc.、Sanofi SA、SGPharma Pvt.Ltd.、Teva Pharmaceutical Industries Ltd.、Zydus Lifesciences Ltd.、Anavex Life Sciences Corp.、Genix Pharma Pvt.Ltd.、Jolly Healthcare、ORPHELIA Pharmaなどです。また、乳児けいれん治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/infantile-spasms-therapeutics-market-industry-analysis をご覧ください。
当出版社では、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細なイメージを提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

ページTOPに戻る


目次

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global infantile spasms therapeutics market 2018 - 2022
o Exhibit 18: Historic Market Size - Data Table on global infantile spasms therapeutics market 2018 - 2022 ($ million)
o 4.2 Route of Administration Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
o 4.3 Drug Class Segment Analysis 2018 - 2022
o Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 - 2022
o Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
o 4.5 Country Segment Analysis 2018 - 2022
o Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
o Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Parenteral - Market size and forecast 2023-2028
o Exhibit 34: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
o 6.4 Oral - Market size and forecast 2023-2028
o Exhibit 38: Chart on Oral - Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 42: Market opportunity by Route of Administration ($ million)
o Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Drug Class
o 7.1 Market segments
o Exhibit 44: Chart on Drug Class - Market share 2023-2028 (%)
o Exhibit 45: Data Table on Drug Class - Market share 2023-2028 (%)
o 7.2 Comparison by Drug Class
o Exhibit 46: Chart on Comparison by Drug Class
o Exhibit 47: Data Table on Comparison by Drug Class
o 7.3 Anticonvulsants - Market size and forecast 2023-2028
o Exhibit 48: Chart on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
o Exhibit 49: Data Table on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
o Exhibit 50: Chart on Anticonvulsants - Year-over-year growth 2023-2028 (%)
o Exhibit 51: Data Table on Anticonvulsants - Year-over-year growth 2023-2028 (%)
o 7.4 Corticosteroids - Market size and forecast 2023-2028
o Exhibit 52: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
o 7.5 Others - Market size and forecast 2023-2028
o Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by Drug Class
o Exhibit 60: Market opportunity by Drug Class ($ million)
o Exhibit 61: Data Table on Market opportunity by Drug Class ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2023-2028
o Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
o Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
o Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
o 9.4 Europe - Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
o 9.5 Asia - Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o 9.7 US - Market size and forecast 2023-2028
o Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
o 9.8 Germany - Market size and forecast 2023-2028
o Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
o 9.9 UK - Market size and forecast 2023-2028
o Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
o 9.10 France - Market size and forecast 2023-2028
o Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)
o 9.11 China - Market size and forecast 2023-2028
o Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ million)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 Amneal Pharmaceuticals Inc.
o Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
o Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
o Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
o Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
o Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus
o 12.4 Cipla Ltd.
o Exhibit 116: Cipla Ltd. - Overview
o Exhibit 117: Cipla Ltd. - Business segments
o Exhibit 118: Cipla Ltd. - Key news
o Exhibit 119: Cipla Ltd. - Key offerings
o Exhibit 120: Cipla Ltd. - Segment focus
o 12.5 Endo International Plc
o Exhibit 121: Endo International Plc - Overview
o Exhibit 122: Endo International Plc - Business segments
o Exhibit 123: Endo International Plc - Key news
o Exhibit 124: Endo International Plc - Key offerings
o Exhibit 125: Endo International Plc - Segment focus
o 12.6 H Lundbeck AS
o Exhibit 126: H Lundbeck AS - Overview
o Exhibit 127: H Lundbeck AS - Product / Service
o Exhibit 128: H Lundbeck AS - Key offerings
o 12.7 Hetero Labs Ltd.
o Exhibit 129: Hetero Labs Ltd. - Overview
o Exhibit 130: Hetero Labs Ltd. - Product / Service
o Exhibit 131: Hetero Labs Ltd. - Key offerings
o 12.8 Intas Pharmaceuticals Ltd.
o Exhibit 132: Intas Pharmaceuticals Ltd. - Overview
o Exhibit 133: Intas Pharmaceuticals Ltd. - Product / Service
o Exhibit 134: Intas Pharmaceuticals Ltd. - Key offerings
o 12.9 Jazz Pharmaceuticals Plc
o Exhibit 135: Jazz Pharmaceuticals Plc - Overview
o Exhibit 136: Jazz Pharmaceuticals Plc - Product / Service
o Exhibit 137: Jazz Pharmaceuticals Plc - Key news
o Exhibit 138: Jazz Pharmaceuticals Plc - Key offerings
o 12.10 Mallinckrodt Plc
o Exhibit 139: Mallinckrodt Plc - Overview
o Exhibit 140: Mallinckrodt Plc - Business segments
o Exhibit 141: Mallinckrodt Plc - Key offerings
o Exhibit 142: Mallinckrodt Plc - Segment focus
o 12.11 Marinus Pharmaceuticals Inc.
o Exhibit 143: Marinus Pharmaceuticals Inc. - Overview
o Exhibit 144: Marinus Pharmaceuticals Inc. - Product / Service
o Exhibit 145: Marinus Pharmaceuticals Inc. - Key offerings
o 12.12 MSN Laboratories
o Exhibit 146: MSN Laboratories - Overview
o Exhibit 147: MSN Laboratories - Product / Service
o Exhibit 148: MSN Laboratories - Key offerings
o 12.13 Ovid Therapeutics Inc.
o Exhibit 149: Ovid Therapeutics Inc. - Overview
o Exhibit 150: Ovid Therapeutics Inc. - Product / Service
o Exhibit 151: Ovid Therapeutics Inc. - Key offerings
o 12.14 Sanofi SA
o Exhibit 152: Sanofi SA - Overview
o Exhibit 153: Sanofi SA - Business segments
o Exhibit 154: Sanofi SA - Key news
o Exhibit 155: Sanofi SA - Key offerings
o Exhibit 156: Sanofi SA - Segment focus
o 12.15 SGPharma Pvt. Ltd.
o Exhibit 157: SGPharma Pvt. Ltd. - Overview
o Exhibit 158: SGPharma Pvt. Ltd. - Product / Service
o Exhibit 159: SGPharma Pvt. Ltd. - Key offerings
o 12.16 Teva Pharmaceutical Industries Ltd.
o Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
o Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
o Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
o Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
o Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
o 12.17 Zydus Lifesciences Ltd.
o Exhibit 165: Zydus Lifesciences Ltd. - Overview
o Exhibit 166: Zydus Lifesciences Ltd. - Business segments
o Exhibit 167: Zydus Lifesciences Ltd. - Key offerings
o Exhibit 168: Zydus Lifesciences Ltd. - Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 169: Inclusions checklist
o Exhibit 170: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 171: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 172: Research methodology
o Exhibit 173: Validation techniques employed for market sizing
o Exhibit 174: Information sources
o 13.5 List of abbreviations
o Exhibit 175: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size - Data Table on global infantile spasms therapeutics market 2018 - 2022 ($ million)
Exhibits19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
Exhibits20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits23: Five forces analysis - Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition - Five forces 2023 and 2028
Exhibits30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibits31: Data Table on Route of Administration - Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
Exhibits42: Market opportunity by Route of Administration ($ million)
Exhibits43: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits44: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits45: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits46: Chart on Comparison by Drug Class
Exhibits47: Data Table on Comparison by Drug Class
Exhibits48: Chart on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
Exhibits49: Data Table on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
Exhibits50: Chart on Anticonvulsants - Year-over-year growth 2023-2028 (%)
Exhibits51: Data Table on Anticonvulsants - Year-over-year growth 2023-2028 (%)
Exhibits52: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by Drug Class ($ million)
Exhibits61: Data Table on Market opportunity by Drug Class ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on France - Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ million)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: Amneal Pharmaceuticals Inc. - Overview
Exhibits112: Amneal Pharmaceuticals Inc. - Business segments
Exhibits113: Amneal Pharmaceuticals Inc. - Key news
Exhibits114: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits115: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits116: Cipla Ltd. - Overview
Exhibits117: Cipla Ltd. - Business segments
Exhibits118: Cipla Ltd. - Key news
Exhibits119: Cipla Ltd. - Key offerings
Exhibits120: Cipla Ltd. - Segment focus
Exhibits121: Endo International Plc - Overview
Exhibits122: Endo International Plc - Business segments
Exhibits123: Endo International Plc - Key news
Exhibits124: Endo International Plc - Key offerings
Exhibits125: Endo International Plc - Segment focus
Exhibits126: H Lundbeck AS - Overview
Exhibits127: H Lundbeck AS - Product / Service
Exhibits128: H Lundbeck AS - Key offerings
Exhibits129: Hetero Labs Ltd. - Overview
Exhibits130: Hetero Labs Ltd. - Product / Service
Exhibits131: Hetero Labs Ltd. - Key offerings
Exhibits132: Intas Pharmaceuticals Ltd. - Overview
Exhibits133: Intas Pharmaceuticals Ltd. - Product / Service
Exhibits134: Intas Pharmaceuticals Ltd. - Key offerings
Exhibits135: Jazz Pharmaceuticals Plc - Overview
Exhibits136: Jazz Pharmaceuticals Plc - Product / Service
Exhibits137: Jazz Pharmaceuticals Plc - Key news
Exhibits138: Jazz Pharmaceuticals Plc - Key offerings
Exhibits139: Mallinckrodt Plc - Overview
Exhibits140: Mallinckrodt Plc - Business segments
Exhibits141: Mallinckrodt Plc - Key offerings
Exhibits142: Mallinckrodt Plc - Segment focus
Exhibits143: Marinus Pharmaceuticals Inc. - Overview
Exhibits144: Marinus Pharmaceuticals Inc. - Product / Service
Exhibits145: Marinus Pharmaceuticals Inc. - Key offerings
Exhibits146: MSN Laboratories - Overview
Exhibits147: MSN Laboratories - Product / Service
Exhibits148: MSN Laboratories - Key offerings
Exhibits149: Ovid Therapeutics Inc. - Overview
Exhibits150: Ovid Therapeutics Inc. - Product / Service
Exhibits151: Ovid Therapeutics Inc. - Key offerings
Exhibits152: Sanofi SA - Overview
Exhibits153: Sanofi SA - Business segments
Exhibits154: Sanofi SA - Key news
Exhibits155: Sanofi SA - Key offerings
Exhibits156: Sanofi SA - Segment focus
Exhibits157: SGPharma Pvt. Ltd. - Overview
Exhibits158: SGPharma Pvt. Ltd. - Product / Service
Exhibits159: SGPharma Pvt. Ltd. - Key offerings
Exhibits160: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits161: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits162: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits163: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits164: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits165: Zydus Lifesciences Ltd. - Overview
Exhibits166: Zydus Lifesciences Ltd. - Business segments
Exhibits167: Zydus Lifesciences Ltd. - Key offerings
Exhibits168: Zydus Lifesciences Ltd. - Segment focus
Exhibits169: Inclusions checklist
Exhibits170: Exclusions checklist
Exhibits171: Currency conversion rates for US$
Exhibits172: Research methodology
Exhibits173: Validation techniques employed for market sizing
Exhibits174: Information sources
Exhibits175: List of abbreviations

 

ページTOPに戻る


 

Summary

Global Infantile Spasms Therapeutics Market 2024-2028
The infantile spasms therapeutics market is forecasted to grow by USD 89.61 mn during 2023-2028, accelerating at a CAGR of 5.41% during the forecast period. The report on the infantile spasms therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in research in neurology and epilepsy, growing demand for infantile spasms therapeutics due to the rising prevalence of infantile spasms and related neurological disorders, and increasing awareness and emphasis on early diagnosis of infantile spasms.
Technavio's infantile spasms therapeutics market is segmented as below:
By Route Of Administration
• Parenteral
• Oral
By Drug Class
• Anticonvulsants
• Corticosteroids
• Others
By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the growing interest in gene therapy as one of the prime reasons driving the infantile spasms therapeutics market growth during the next few years. Also, increasing integration of digital health solutions and advancements in infantile spasms therapeutics due to collaborations between pharmaceutical companies, research institutions, and advocacy groups will lead to sizable demand in the market.
The report on the infantile spasms therapeutics market covers the following areas:
• Infantile spasms therapeutics market sizing
• Infantile spasms therapeutics market forecast
• Infantile spasms therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading infantile spasms therapeutics market vendors that include Amneal Pharmaceuticals Inc., Cipla Ltd., Endo International Plc, H Lundbeck AS, Hetero Labs Ltd., Intas Pharmaceuticals Ltd., Jazz Pharmaceuticals Plc, Mallinckrodt Plc, Marinus Pharmaceuticals Inc., MSN Laboratories, Ovid Therapeutics Inc., Sanofi SA, SGPharma Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Anavex Life Sciences Corp., Genix Pharma Pvt. Ltd., Jolly Healthcare, and ORPHELIA Pharma. Also, the infantile spasms therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/infantile-spasms-therapeutics-market-industry-analysis
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.



ページTOPに戻る


Table of Contents

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global infantile spasms therapeutics market 2018 - 2022
o Exhibit 18: Historic Market Size - Data Table on global infantile spasms therapeutics market 2018 - 2022 ($ million)
o 4.2 Route of Administration Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
o 4.3 Drug Class Segment Analysis 2018 - 2022
o Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 - 2022
o Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
o 4.5 Country Segment Analysis 2018 - 2022
o Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
o Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Parenteral - Market size and forecast 2023-2028
o Exhibit 34: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
o 6.4 Oral - Market size and forecast 2023-2028
o Exhibit 38: Chart on Oral - Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 42: Market opportunity by Route of Administration ($ million)
o Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Drug Class
o 7.1 Market segments
o Exhibit 44: Chart on Drug Class - Market share 2023-2028 (%)
o Exhibit 45: Data Table on Drug Class - Market share 2023-2028 (%)
o 7.2 Comparison by Drug Class
o Exhibit 46: Chart on Comparison by Drug Class
o Exhibit 47: Data Table on Comparison by Drug Class
o 7.3 Anticonvulsants - Market size and forecast 2023-2028
o Exhibit 48: Chart on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
o Exhibit 49: Data Table on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
o Exhibit 50: Chart on Anticonvulsants - Year-over-year growth 2023-2028 (%)
o Exhibit 51: Data Table on Anticonvulsants - Year-over-year growth 2023-2028 (%)
o 7.4 Corticosteroids - Market size and forecast 2023-2028
o Exhibit 52: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
o 7.5 Others - Market size and forecast 2023-2028
o Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by Drug Class
o Exhibit 60: Market opportunity by Drug Class ($ million)
o Exhibit 61: Data Table on Market opportunity by Drug Class ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2023-2028
o Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
o Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
o Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
o 9.4 Europe - Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
o 9.5 Asia - Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o 9.7 US - Market size and forecast 2023-2028
o Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
o 9.8 Germany - Market size and forecast 2023-2028
o Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
o 9.9 UK - Market size and forecast 2023-2028
o Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
o 9.10 France - Market size and forecast 2023-2028
o Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)
o 9.11 China - Market size and forecast 2023-2028
o Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ million)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 Amneal Pharmaceuticals Inc.
o Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
o Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
o Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
o Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
o Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus
o 12.4 Cipla Ltd.
o Exhibit 116: Cipla Ltd. - Overview
o Exhibit 117: Cipla Ltd. - Business segments
o Exhibit 118: Cipla Ltd. - Key news
o Exhibit 119: Cipla Ltd. - Key offerings
o Exhibit 120: Cipla Ltd. - Segment focus
o 12.5 Endo International Plc
o Exhibit 121: Endo International Plc - Overview
o Exhibit 122: Endo International Plc - Business segments
o Exhibit 123: Endo International Plc - Key news
o Exhibit 124: Endo International Plc - Key offerings
o Exhibit 125: Endo International Plc - Segment focus
o 12.6 H Lundbeck AS
o Exhibit 126: H Lundbeck AS - Overview
o Exhibit 127: H Lundbeck AS - Product / Service
o Exhibit 128: H Lundbeck AS - Key offerings
o 12.7 Hetero Labs Ltd.
o Exhibit 129: Hetero Labs Ltd. - Overview
o Exhibit 130: Hetero Labs Ltd. - Product / Service
o Exhibit 131: Hetero Labs Ltd. - Key offerings
o 12.8 Intas Pharmaceuticals Ltd.
o Exhibit 132: Intas Pharmaceuticals Ltd. - Overview
o Exhibit 133: Intas Pharmaceuticals Ltd. - Product / Service
o Exhibit 134: Intas Pharmaceuticals Ltd. - Key offerings
o 12.9 Jazz Pharmaceuticals Plc
o Exhibit 135: Jazz Pharmaceuticals Plc - Overview
o Exhibit 136: Jazz Pharmaceuticals Plc - Product / Service
o Exhibit 137: Jazz Pharmaceuticals Plc - Key news
o Exhibit 138: Jazz Pharmaceuticals Plc - Key offerings
o 12.10 Mallinckrodt Plc
o Exhibit 139: Mallinckrodt Plc - Overview
o Exhibit 140: Mallinckrodt Plc - Business segments
o Exhibit 141: Mallinckrodt Plc - Key offerings
o Exhibit 142: Mallinckrodt Plc - Segment focus
o 12.11 Marinus Pharmaceuticals Inc.
o Exhibit 143: Marinus Pharmaceuticals Inc. - Overview
o Exhibit 144: Marinus Pharmaceuticals Inc. - Product / Service
o Exhibit 145: Marinus Pharmaceuticals Inc. - Key offerings
o 12.12 MSN Laboratories
o Exhibit 146: MSN Laboratories - Overview
o Exhibit 147: MSN Laboratories - Product / Service
o Exhibit 148: MSN Laboratories - Key offerings
o 12.13 Ovid Therapeutics Inc.
o Exhibit 149: Ovid Therapeutics Inc. - Overview
o Exhibit 150: Ovid Therapeutics Inc. - Product / Service
o Exhibit 151: Ovid Therapeutics Inc. - Key offerings
o 12.14 Sanofi SA
o Exhibit 152: Sanofi SA - Overview
o Exhibit 153: Sanofi SA - Business segments
o Exhibit 154: Sanofi SA - Key news
o Exhibit 155: Sanofi SA - Key offerings
o Exhibit 156: Sanofi SA - Segment focus
o 12.15 SGPharma Pvt. Ltd.
o Exhibit 157: SGPharma Pvt. Ltd. - Overview
o Exhibit 158: SGPharma Pvt. Ltd. - Product / Service
o Exhibit 159: SGPharma Pvt. Ltd. - Key offerings
o 12.16 Teva Pharmaceutical Industries Ltd.
o Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
o Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
o Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
o Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
o Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
o 12.17 Zydus Lifesciences Ltd.
o Exhibit 165: Zydus Lifesciences Ltd. - Overview
o Exhibit 166: Zydus Lifesciences Ltd. - Business segments
o Exhibit 167: Zydus Lifesciences Ltd. - Key offerings
o Exhibit 168: Zydus Lifesciences Ltd. - Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 169: Inclusions checklist
o Exhibit 170: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 171: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 172: Research methodology
o Exhibit 173: Validation techniques employed for market sizing
o Exhibit 174: Information sources
o 13.5 List of abbreviations
o Exhibit 175: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size - Data Table on global infantile spasms therapeutics market 2018 - 2022 ($ million)
Exhibits19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
Exhibits20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits23: Five forces analysis - Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition - Five forces 2023 and 2028
Exhibits30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibits31: Data Table on Route of Administration - Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
Exhibits42: Market opportunity by Route of Administration ($ million)
Exhibits43: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits44: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits45: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits46: Chart on Comparison by Drug Class
Exhibits47: Data Table on Comparison by Drug Class
Exhibits48: Chart on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
Exhibits49: Data Table on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
Exhibits50: Chart on Anticonvulsants - Year-over-year growth 2023-2028 (%)
Exhibits51: Data Table on Anticonvulsants - Year-over-year growth 2023-2028 (%)
Exhibits52: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by Drug Class ($ million)
Exhibits61: Data Table on Market opportunity by Drug Class ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on France - Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ million)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: Amneal Pharmaceuticals Inc. - Overview
Exhibits112: Amneal Pharmaceuticals Inc. - Business segments
Exhibits113: Amneal Pharmaceuticals Inc. - Key news
Exhibits114: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits115: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits116: Cipla Ltd. - Overview
Exhibits117: Cipla Ltd. - Business segments
Exhibits118: Cipla Ltd. - Key news
Exhibits119: Cipla Ltd. - Key offerings
Exhibits120: Cipla Ltd. - Segment focus
Exhibits121: Endo International Plc - Overview
Exhibits122: Endo International Plc - Business segments
Exhibits123: Endo International Plc - Key news
Exhibits124: Endo International Plc - Key offerings
Exhibits125: Endo International Plc - Segment focus
Exhibits126: H Lundbeck AS - Overview
Exhibits127: H Lundbeck AS - Product / Service
Exhibits128: H Lundbeck AS - Key offerings
Exhibits129: Hetero Labs Ltd. - Overview
Exhibits130: Hetero Labs Ltd. - Product / Service
Exhibits131: Hetero Labs Ltd. - Key offerings
Exhibits132: Intas Pharmaceuticals Ltd. - Overview
Exhibits133: Intas Pharmaceuticals Ltd. - Product / Service
Exhibits134: Intas Pharmaceuticals Ltd. - Key offerings
Exhibits135: Jazz Pharmaceuticals Plc - Overview
Exhibits136: Jazz Pharmaceuticals Plc - Product / Service
Exhibits137: Jazz Pharmaceuticals Plc - Key news
Exhibits138: Jazz Pharmaceuticals Plc - Key offerings
Exhibits139: Mallinckrodt Plc - Overview
Exhibits140: Mallinckrodt Plc - Business segments
Exhibits141: Mallinckrodt Plc - Key offerings
Exhibits142: Mallinckrodt Plc - Segment focus
Exhibits143: Marinus Pharmaceuticals Inc. - Overview
Exhibits144: Marinus Pharmaceuticals Inc. - Product / Service
Exhibits145: Marinus Pharmaceuticals Inc. - Key offerings
Exhibits146: MSN Laboratories - Overview
Exhibits147: MSN Laboratories - Product / Service
Exhibits148: MSN Laboratories - Key offerings
Exhibits149: Ovid Therapeutics Inc. - Overview
Exhibits150: Ovid Therapeutics Inc. - Product / Service
Exhibits151: Ovid Therapeutics Inc. - Key offerings
Exhibits152: Sanofi SA - Overview
Exhibits153: Sanofi SA - Business segments
Exhibits154: Sanofi SA - Key news
Exhibits155: Sanofi SA - Key offerings
Exhibits156: Sanofi SA - Segment focus
Exhibits157: SGPharma Pvt. Ltd. - Overview
Exhibits158: SGPharma Pvt. Ltd. - Product / Service
Exhibits159: SGPharma Pvt. Ltd. - Key offerings
Exhibits160: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits161: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits162: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits163: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits164: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits165: Zydus Lifesciences Ltd. - Overview
Exhibits166: Zydus Lifesciences Ltd. - Business segments
Exhibits167: Zydus Lifesciences Ltd. - Key offerings
Exhibits168: Zydus Lifesciences Ltd. - Segment focus
Exhibits169: Inclusions checklist
Exhibits170: Exclusions checklist
Exhibits171: Currency conversion rates for US$
Exhibits172: Research methodology
Exhibits173: Validation techniques employed for market sizing
Exhibits174: Information sources
Exhibits175: List of abbreviations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(spasms therapeutics)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


TechNavio社はどのような調査会社ですか?


テクナビオ(TechNavio)は英国ロンドンに本社をおく幅広い市場を調査対象とする調査会社インフィニティリサーチ社(Infiniti Research)の調査レポート出版部門です。データリソースはT... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/18 10:27

154.74 円

162.88 円

199.42 円

ページTOPに戻る